Authors
Tineke Casneuf, Homer C Adams III, Niels WCJ van de Donk, Yann Abraham, Jaime Bald, Greet Vanhoof, Koen Van der Borght, Tina Smets, Brad Foulk, Karl C Nielsen, Joshua Rusbuldt, Amy Axel, Andrew Lysaght, Hugo Ceulemans, Frederik Stevenaert, Saad Z Usmani, Torben Plesner, Herve Avet-Loiseau, Inger Nijhof, Tuna Mutis, Jordan M Schecter, Christopher Chiu, Nizar J Bahlis
Publication date
2021/2
Journal
Leukemia
Volume
35
Issue
2
Pages
573-584
Publisher
Nature Publishing Group UK
Description
CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune response, reducing natural killer (NK) cells without affecting efficacy or safety. We further evaluated daratumumab’s effects on immune cells in whole blood samples of relapsed/refractory MM patients from both treatment arms of the phase 3 POLLUX study (lenalidomide/dexamethasone [Rd] or daratumumab plus Rd [D-Rd]) at baseline (D-Rd, 40; Rd, 45) and after 2 months on treatment (D-Rd, 31; Rd, 33) using cytometry by time-of-flight. We confirmed previous reports of NK cell reduction with D-Rd. Persisting NK cells were phenotypically distinct, with increased expression of HLA-DR, CD69, CD127, and CD27. The proportion of T cells increased preferentially in deep …
Scholar articles
T Casneuf, HC Adams III, NWCJ van de Donk… - Leukemia, 2021